There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
To read the full story
Related Article
- Kyowa Kirin’s Parkinson’s Med Rejected Again in Europe
November 16, 2021
- European Panel Rejects Kyowa Kirin’s Parkinson’s Med
July 29, 2021
- Kyowa Kirin’s Parkinson’s Med Accepted for Review in Europe
January 7, 2020
- FDA Accepts NDA Resubmission for Parkinson’s Drug Istradefylline: Kyowa Kirin
April 8, 2019
- Kyowa Kirin Resubmits Istradefylline for US Approval for 1st time in 12 Years, Based on Japanese Data
March 4, 2019
- Parkinson’s Med Nouriast Fails in PIII Study in US, Europe: Kyowa Kirin
December 14, 2016
- Kyowa Hakko Receives Not-Approvable Letter from FDA for Istradefylline
March 10, 2008
- Kyowa Hakko Submits NDA for KW-6002 Combination Therapy for Parkinson's Disease in US
May 14, 2007
BUSINESS
- Edirol’s Tablet Forms Approved in Japan, Towa Responsible for Distribution
August 16, 2022
- US Arbitrator Rejects Seagen’s Claims against Daiichi Sankyo in ADC Feud
August 16, 2022
- UCB Files E Keppra for Children Aged One Month or Older
August 15, 2022
- Enhertu Gets Accelerated FDA Approval for 2nd Line NSCLC Use
August 15, 2022
- Chugai Gets Priority Review for PNH Med Crovalimab in China
August 12, 2022
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…